ICON PLC (ICLR) - Total Liabilities
Based on the latest financial reports, ICON PLC (ICLR) has total liabilities worth $7.17 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ICON PLC cash conversion from operations to assess how effectively this company generates cash.
ICON PLC - Total Liabilities Trend (1998–2024)
This chart illustrates how ICON PLC's total liabilities have evolved over time, based on quarterly financial data. Check ICON PLC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
ICON PLC Competitors by Total Liabilities
The table below lists competitors of ICON PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Svenska Cellulosa Aktiebolaget SCA (publ)
ST:SCA-B
|
Sweden | Skr44.94 Billion |
|
Dutch Bros Inc
NYSE:BROS
|
USA | $2.11 Billion |
|
Sangfor Technologies Inc Class A
SHE:300454
|
China | CN¥5.67 Billion |
|
Huadian Power International Corp Ltd Class A
SHG:600027
|
China | CN¥163.00 Billion |
|
Huadian Energy
SHG:600726
|
China | CN¥25.25 Billion |
|
Telekom Malaysia Bhd
KLSE:4863
|
Malaysia | RM9.70 Billion |
|
STAG Industrial Inc
NYSE:STAG
|
USA | $3.40 Billion |
Liability Composition Analysis (1998–2024)
This chart breaks down ICON PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ICON PLC stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ICON PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ICON PLC (1998–2024)
The table below shows the annual total liabilities of ICON PLC from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.35 Billion | -5.09% |
| 2023-12-31 | $7.75 Billion | -10.80% |
| 2022-12-31 | $8.69 Billion | -6.79% |
| 2021-12-31 | $9.32 Billion | +487.89% |
| 2020-12-31 | $1.59 Billion | +22.95% |
| 2019-12-31 | $1.29 Billion | +28.95% |
| 2018-12-31 | $999.97 Million | +4.64% |
| 2017-12-31 | $955.62 Million | +8.51% |
| 2016-12-31 | $880.67 Million | -7.76% |
| 2015-12-31 | $954.71 Million | +65.29% |
| 2014-12-31 | $577.59 Million | +8.59% |
| 2013-12-31 | $531.88 Million | +18.85% |
| 2012-12-31 | $447.53 Million | +26.45% |
| 2011-12-31 | $353.92 Million | +26.61% |
| 2010-12-31 | $279.54 Million | -16.84% |
| 2009-12-31 | $336.15 Million | -18.20% |
| 2008-12-31 | $410.92 Million | +35.42% |
| 2007-12-31 | $303.43 Million | +75.92% |
| 2006-12-31 | $172.48 Million | +61.78% |
| 2005-12-31 | $106.61 Million | -10.08% |
| 2004-12-31 | $118.56 Million | +73.19% |
| 2003-12-31 | $68.46 Million | -30.22% |
| 2002-12-31 | $98.10 Million | +88.76% |
| 2001-12-31 | $51.97 Million | +67.49% |
| 2000-12-31 | $31.03 Million | +34.53% |
| 1999-12-31 | $23.07 Million | -1.85% |
| 1998-12-31 | $23.50 Million | -- |
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more